Abstract
Fenofibrate is an effective and safe treatment for hypertriglyceridemia. However, after TG reduction a residual dyslipidemia could appear and require further treatment. To comparatively evaluate the short-term tolerability and efficacy of a combined lipid-lowering nutraceutical and pravastatin 40 mg in fenofibrate treated patients. We prospectively enrolled 40 patients well-tolerating treatment with micronized fenofibrate 145 mg/day and with residual dyslipidemia (LDL-C > 115 mg/dL and TG > 150 mg/dL). Exclusion criteria have been type 2 diabetes, Familial Hypercholesterolemia, previous cardiovascular diseases and severe chronic kidney disease. Then, we have randomly assigned the patients to treatment with pravastatin 40 mg or a combined lipid-lowering nutraceutical (Armolipid Plus®, containing monacolin 3 mg and berberine 500 mg). After 8 weeks of treatment, 80% of pravastatin treated patients (N. 16/20) and 75% of those treated with Armolipid Plus® (N. 15/20) reached the desired LDL-C target, while 50% of pravastatin treated patients (N. 10/20) and 80% of the Armolipid Plus® treated ones reached the desired TG target (N. 16/20). No one adverse event has been registered during Armolipid Plus®, while 1 patient claimed myalgia a...Continue Reading
References
Sep 24, 2008·Expert Opinion on Investigational Drugs·Theodosios Filippatos, Haralampos J Milionis
Jan 18, 2013·Clinical and Experimental Pharmacology & Physiology·Qiang GengWenqing Liang
Jun 19, 2013·European Heart Journal·Giuseppe ManciaDavid A Wood
Jul 22, 2014·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Antonio Hernández Mijares
Sep 20, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Giuseppe DerosaAmirhossein Sahebkar
May 10, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Matteo PirroAmirhossein Sahebkar
May 18, 2016·The American Journal of Cardiology·Matthew Budoff
Jun 21, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Amirhossein SahebkarLuisa Costanzo
Sep 1, 2016·Journal of Clinical Lipidology·Kevin C MakiMichael H Davidson
Sep 7, 2016·Atherosclerosis·UNKNOWN Authors/Task Force Members:Jose Luis Zamorano
Dec 22, 2016·Atherosclerosis. Supplements·Vivencio BarriosEric Bruckert
Mar 1, 2017·Vascular Health and Risk Management·Nicola TarantinoNatale Daniele Brunetti
Apr 30, 2017·Journal of Atherosclerosis and Thrombosis·Atsushi ShinnakasuYoshihiko Nishio
May 26, 2017·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Arrigo Francesco Giuseppe CiceroClaudio Borghi
Sep 9, 2017·Archives of Medical Science : AMS·Arrigo F G CiceroMaciej Banach
Oct 13, 2017·Nutrition & Metabolism·Arrigo F G CiceroClaudio Borghi
Jun 30, 2018·Journal of the American College of Cardiology·Maciej BanachUNKNOWN International Lipid Expert Panel (ILEP)